How N-Acetylcysteine is specified, controlled, documented and released.
| Pharmacopoeia | Status |
|---|---|
| ChP | Available |
| USP | Available |
| EP | Available |
Assay limits, impurity profiles and test methods follow the current edition of each pharmacopoeia. Batch-specific results are reported on the certificate of analysis.
Certificates not held or no longer valid are not listed. Items under application are marked as such.
| Document | Status |
|---|---|
| Certificate of Analysis (COA) — 3 commercial batches | Available |
| Drug Master File (ChP / USP / EP) | Available |
| Written Confirmation (WC) — EU | Available |
| COPP | Available |
| GMP certificate | Available |
| CTD Module 3 (S.1–S.7) | Available |
| Stability data — ICH Q1A, Zone II & IVb | Available |
| TSE / BSE & GMO free statement | Available |
| ICH Q3C / Q3D & nitrosamine assessment | Available |
| CEP (EDQM) | In application |
The statements on this page describe documentation status, not product approval. References to pharmacopoeial compliance do not constitute approval by any regulatory authority.
Tell us grade, pharmacopoeia, quantity and destination. We reply with COA sample, MSDS and a price proposal.
